NASDAQ:ALLO Allogene Therapeutics (ALLO) Stock Price, News & Analysis $3.00 +0.09 (+3.09%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.86▼$3.0550-Day Range$2.08▼$3.5052-Week Range$2.01▼$5.78Volume1.59 million shsAverage Volume2.73 million shsMarket Capitalization$627 millionP/E RatioN/ADividend YieldN/APrice Target$9.95 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Allogene Therapeutics alerts: Email Address Allogene Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside231.7% Upside$9.95 Price TargetShort InterestBearish31.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.21Based on 3 Articles This WeekInsider TradingAcquiring Shares$5 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.50) to ($1.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector310th out of 936 stocksBiological Products, Except Diagnostic Industry42nd out of 154 stocks 4.4 Analyst's Opinion Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAllogene Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Allogene Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted31.63% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 4.47%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLO. Previous Next 2.9 News and Social Media Coverage News SentimentAllogene Therapeutics has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Allogene Therapeutics this week, compared to 3 articles on an average week.Search Interest20 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have bought 18,978.13% more of their company's stock than they have sold. Specifically, they have bought $4,999,997.00 in company stock and sold $26,208.00 in company stock.Percentage Held by Insiders24.30% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allogene Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($1.50) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Allogene Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Allogene Therapeutics Stock (NASDAQ:ALLO)Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Read More ALLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLO Stock News HeadlinesJuly 24 at 11:35 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Ocular Therapeutix (OCUL) and Repare Therapeutics (RPTX)July 21, 2024 | americanbankingnews.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 18, 2024 | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Sees Large Volume IncreaseJuly 1, 2024 | globenewswire.comAllogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)June 20, 2024 | globenewswire.comAllogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to RelapseJune 12, 2024 | seekingalpha.comAllogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T ProductsMay 29, 2024 | finance.yahoo.comInsiders Pour Millions Into These 2 ‘Strong Buy’ StocksJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 28, 2024 | investorplace.comIf You Can Only Buy One Penny Stock in May, It Better Be One of These 3 NamesMay 26, 2024 | 247wallst.comInsider Buying of These 6 Stocks Surges: Fracking, Boats, a Buyout CandidateMay 23, 2024 | markets.businessinsider.comAllogene Therapeutics Hold Rating: Balancing Financials and Clinical Development ProgressMay 23, 2024 | globenewswire.comAllogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation SummitMay 21, 2024 | marketwatch.comAllogene Therapeutics Shares Jump 10% on Share Purchases by Chairman, CEOMay 21, 2024 | msn.comInsider Trading: Allogene Therapeutics’ Insider Buys Shares Worth $5MMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Allogene Therapeutics Amidst Pipeline Progress and Strategic ExpansionMay 15, 2024 | markets.businessinsider.comBreaking Down Allogene Therapeutics: 5 Analysts Share Their ViewsMay 14, 2024 | msn.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2024 Earnings Call TranscriptSee More Headlines Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALLO CUSIPN/A CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees232Year Founded2018Price Target and Rating Average Stock Price Target$9.95 High Stock Price Target$17.00 Low Stock Price Target$4.60 Potential Upside/Downside+231.7%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-327,270,000.00 Net Margins-223,139.98% Pretax Margin-224,843.84% Return on Equity-50.81% Return on Assets-40.82% Debt Debt-to-Equity RatioN/A Current Ratio12.80 Quick Ratio12.80 Sales & Book Value Annual Sales$90,000.00 Price / Sales6,966.67 Cash FlowN/A Price / Cash FlowN/A Book Value$3.04 per share Price / Book0.99Miscellaneous Outstanding Shares209,000,000Free Float158,213,000Market Cap$627 million OptionableOptionable Beta0.85 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Arie S. Belldegrun F.A.C.S. (Age 75)M.D., Co-Founder & Executive Chairman Comp: $649.1kDr. David D. Chang M.D. (Age 64)Ph.D., Co-Founder, President, CEO & Director Comp: $994.6kMr. Joshua A. Kazam (Age 47)Co-Founder & Director Comp: $260.5kMr. Timothy L. Moore Ph.D. (Age 63)Executive VP & Chief Technical Officer Comp: $554.35kDr. Zachary J. Roberts M.D. (Age 46)Ph.D., Executive VP of Research & Development and Chief Medical Officer Comp: $747.39kMr. Geoffrey M. Parker (Age 59)Executive VP & CFO Mr. Earl M. Douglas Esq. (Age 61)Senior VP, General Counsel, Compliance Officer & Corporate Secretary Ms. Susan R. Lundeen (Age 58)Chief People Officer Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy OfficerYinlin ChenSenior Vice President of FinanceMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEVericelNASDAQ:VCELBeam TherapeuticsNASDAQ:BEAMIovance BiotherapeuticsNASDAQ:IOVANovavaxNASDAQ:NVAXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 61,811 shares on 7/26/2024Ownership: 0.173%Nisa Investment Advisors LLCBought 8,734 shares on 7/20/2024Ownership: 0.005%Phoenix Wealth AdvisorsBought 13,000 shares on 7/17/2024Ownership: 0.006%SG Americas Securities LLCSold 21,842 shares on 7/12/2024Ownership: 0.006%Bourgeon Capital Management LLCBought 75,255 shares on 7/11/2024Ownership: 0.063%View All Insider TransactionsView All Institutional Transactions ALLO Stock Analysis - Frequently Asked Questions How have ALLO shares performed this year? Allogene Therapeutics' stock was trading at $3.21 at the start of the year. Since then, ALLO shares have decreased by 6.5% and is now trading at $3.00. View the best growth stocks for 2024 here. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03. The company's revenue was down 26.7% compared to the same quarter last year. What is David Chang's approval rating as Allogene Therapeutics' CEO? 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Allogene Therapeutics IPO? Allogene Therapeutics (ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO. Who are Allogene Therapeutics' major shareholders? Top institutional shareholders of Allogene Therapeutics include Bank of New York Mellon Corp (0.17%), Bourgeon Capital Management LLC (0.06%), SG Americas Securities LLC (0.01%) and Phoenix Wealth Advisors (0.01%). Insiders that own company stock include Arie Belldegrun, Veer Bhavnagri, Rafael Amado, Franz B Humer, Owen N Witte, David D Chang, Eric Thomas Schmidt and Alison Moore. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC) and AbbVie (ABBV). This page (NASDAQ:ALLO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
